Overview
Alpha-N-acetylgalactosaminidase deficiency type 2, also known as Schindler disease type 2, is a rare lysosomal storage disorder characterized by a deficiency in the enzyme alpha-N-acetylgalactosaminidase, leading to the accumulation of glycolipids and glycoproteins, primarily affecting neurons and potentially causing progressive neurological symptoms 1.Diagnosis
Enzymatic assay to measure alpha-N-acetylgalactosaminidase activity in leukocytes or fibroblasts 1.
Genetic testing for mutations in the MAN2B1 gene 1.
Clinical evaluation focusing on neurological manifestations such as ataxia, dystonia, and cognitive decline 1.Management
No specific pharmacological treatments are mentioned in the provided abstracts 1.
Supportive care focusing on managing symptoms and complications 1.
Enzyme replacement therapy is not discussed in the context of this specific enzyme deficiency 1.Special Populations
No specific information provided regarding pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.Key Recommendations
Confirm diagnosis through enzymatic activity testing and genetic analysis of MAN2B1 gene (Evidence: Expert opinion) 1.
Implement supportive care strategies tailored to neurological symptoms (Evidence: Expert opinion) 1.
Monitor and manage complications as they arise, given the lack of specific therapeutic interventions (Evidence: Expert opinion) 1.References
1 Tibbot BK, Henson CA, Skadsen RW. Expression of enzymatically active, recombinant barley alpha-glucosidase in yeast and immunological detection of alpha-glucosidase from seed tissue. Plant molecular biology 1998. link